CD276 and neuroblastoma: With the emergence of promising clinical trials targeting B7-H3-positive malignancies, such as the use of the radiolabeled monoclonal antibody (mAb) 131I-omburtamab on neuroblastoma patients (Kramer et al., 2022), B7-H3 has gained attention as a clinically relevant therapeutic target.